Clovis has confirmed a major victory with its ovarian cancer treatment Rubraca, the drug showing significant benefits for all patients in a maintenance setting – and better results than its rivals.

The price you pay for Rubraca may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Clovis Oncology’s Rubraca (rucaparib) has been designated as a Breakthrough Therapy by the FDA in prostate cancer, paving the way for a faster review if clinical trials work out. The FDA has ...

The National Institute of Health and Care Excellence (NICE) has recommended pharmaand’s (pharma&) Rubraca (rucaparib) as a first-line maintenance treatment option for a subset of advanced ovarian ...